Abstract 876P
Background
Despite surgical resection, Oral Potentially Malignant Disorders show a rate of malignant transformation varying from 3% to 17.5%. Clinical and histological factors outside dysplasia and previous oral cavity carcinoma failed to identify OPMDs at higher risk of malignant transformation (MF). We previously identified six clusters of transcriptomic data able to stratify Head and Neck Squamous Cell Carcinoma (HNSCC) that also applied to OPMD. The primary objective of the current study was to validate the stratification by the transcriptional signature in an independent series of dysplastic OPMD.
Methods
We collected a retrospective series (3/1996 to 11/2019) of completely excised OPMDs with any grade of dysplasia at the University of Brescia. Clinical/histological data were retrieved. Library preparation for gene expression profiling was conducted QuantSeq 3'mrna-seq (Lexogen) and pooled libraries were sequenced by NextSeq500 (Illumina). Finally, previously identified molecular clusters based on main biological characteristics and de-regulated signaling pathways were associated with the risk of MF.
Results
We identified 106 consecutive patients with OPMDs. Of these, 66 had available material for gene expression analysis. A slight majority were male (53.4%), with a median age of 65 years (33-95); 17% had a previous diagnosis of HNSCC. With a median follow-up of 53 months (IQR 91), 23% experienced a MF with a median time to transformation of 30 months (3—195). After stratification based on our previously reported clusters, OPMDs were classified as mesenchymal, hypoxia, defense response, classical, and immunoreactive clusters constituted 8%, 15%, 27%, 9%, and 41% of our cohort, respectively. Hypoxia cluster showed a higher risk of malignant transformation (p<0.0001).
Conclusions
OPMDs gene expression clustering allows stratifying patients according to different risk of MF. Among them, hypoxia cluster had the highest probability of cancerization. A more in-depth analysis of this cluster is required, both to better characterize the mechanisms of MF and to develop customized prevention strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Oncology Unit, Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University of Brescia, ASST Spedali Civili, 25123 Brescia, Italy.
Funding
Funded by AIRC (IG 21740 to PB).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
932P - Survival in patients with relapsed/metastatic head and neck squamous cell carcinoma (HNSCC) treated with pembrolizumab or cetuximab-based therapy: A real-worlddata study with the TriNetX platform
Presenter: Lisardo Ugidos De La Varga
Session: Poster session 12
934P - Antitumor activity and safety profile of camrelizumab plus docetaxel, cisplatin, and capecitabine for induction therapy in advanced stage hypopharyngeal carcinoma
Presenter: Hongli Gong
Session: Poster session 12
938P - Nivolumab (nivo) in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN): real-world effectiveness, quality of life (QoL) of patients and their caregivers in France (ProNiHN study)
Presenter: Christophe Le Tourneau
Session: Poster session 12
939P - Efficacy and safety of a novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell carcinoma of the head and neck patients
Presenter: Liqiong Xue
Session: Poster session 12
940P - Salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck included in the phase II TOPNIVO trial
Presenter: Khalil Saleh
Session: Poster session 12
941P - Risk factors for progressive disease after immune checkpoint inhibitors (ICIs) in advanced head and neck squamous cell carcinoma (HNSCC): Who might not be candidate for ICI?
Presenter: Seo Yoon Jang
Session: Poster session 12